drugset / Trial / NCT04171986
Mecapegfilgrastim Prevents Neutropenia and Radiation Esophagitis
NaSingle-groupOpen-labelPrevention
Summary
Evaluation of the efficacy and safety of Mecapegfilgrastim for the prevention of neutropenia and radiation esophagitis after hyperfractionation in patients with limited-stage small cell lung cancer
Timeline
- Start
- 2019-11-10
- Primary completion
- 2021-10-31
- Completion
- 2021-10-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Mecapegfilgrastim | Protein / enzyme biologic | 6 mg | — |